earnings
confidence high
sentiment negative
materiality 0.65
Co-Diagnostics FY2024 revenue $3.9M, net loss $37.6M; withdraws 510(k) for platform
Co-Diagnostics, Inc.
- Revenue $3.9M vs $6.8M in 2023; product revenue $0.8M, grant revenue $3.1M.
- Net loss $37.6M ($1.24/diluted share) vs $35.3M ($1.20) prior year.
- Adjusted EBITDA loss of $33.5M; operating expenses $43.0M decreased 5.2% YoY.
- Cash and marketable securities $29.7M as of Dec 31, 2024.
- Withdrew initial 510(k) for Co-Dx PCR Pro; plans to resubmit enhanced version.